Yan Leyfman: New Study Alert – CAFs vs NK Cells in Breast Cancer
Yan Leyfman, Co-founder and Executive Director of MedNews Week, posted on X:
“New Study Alert: CAFs vs NK Cells in Breast Cancer
In triple-negative breast cancer, cancer-associated fibroblasts (CAFs) aren’t just bystanders—they actively suppress NK cell cytotoxicity, helping tumors evade immune surveillance.
Key findings:
- CAFs engage NK cells via ligand–receptor interactions
- This reduces NK activating receptors and promotes tumor escape
- CAF-rich areas show NK cell accumulation—but less anti-tumor activity
- High CAF–NK interactions correlate with worse patient outcomes
This “decoy” mechanism reveals a novel immunosuppressive axis—and new opportunities for targeted immunotherapy and biomarker discovery in breast cancer.”
Title: Cancer-Associated Fibroblasts Serve as Decoys to Suppress NK Cell Anticancer Cytotoxicity in Breast Cancer
Authors: Aviad Ben-Shmuel, Yael Gruper, Coral Halperin, Oshrat Levi-Galibov, Hallel Rosenberg-Fogler, Debra Barki, Giulia Carradori, Yaniv Stein, Gal Yagel, Mariia Naumova, Shimrit Mayer, Maya Dadiani, Dana Morzaev-Sulzbach, Ofra Golani, Reinat Nevo, Ziv Porat, Einav Nili Gal-Yam, Ruth Scherz-Shouval
Read The Full Article at AACR Journals.
More posts featuring Yan Leyfman on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023